Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)

David Stamler, M.D., Chief Executive Officer, Alterity Therapeutics

David Stamler, M.D. was appointed Chief Executive Officer in January 2021, He previously served as Alterity’s Chief Medical Officer and Senior Vice President, Clinical Development since May of 2017. Before joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries after Teva acquired Auspex Pharmaceuticals where he was the Chief Medical Officer prior to the acquisition. Previously, Dr. Stamler served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., a publicly traded biopharmaceutical company, and as Chief Scientific Officer and Head of Drug Development at Prestwick Pharmaceuticals, Inc., a private pharmaceutical company. Before Prestwick, Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc., and as Vice President, Clinical Research Center at Fujisawa Research Institute of America. Dr. Stamler began his career at Abbott Laboratories, a publicly traded global pharmaceuticals and healthcare products company, where he served in various positions including Director of Clinical Research, Pharmaceutical Products for the International Division. Dr. Stamler received his M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.

Remy Bernarda, IRC, MBA, Partner, Investor Relations Advisory Solutions

Remy Bernarda has nearly 30 years of experience in finance, investor relations and communications. Over her career, she has initiated and managed investor relations, corporate and clinical communications, and marketing programs for several companies both in-house and as an external advisor. Ms. Bernarda is well-versed in both internal and external communications with extensive experience advising C-Level officers and Boards of Directors on overall corporate strategy, communications and disclosure, crisis management, financing, and operations.Ms. Bernarda began her career on Wall Street working at Goldman Sachs, Knight Equity Markets, and Bear Stearns. She holds an M.B.A. and a B.S. degree in Business Administration from Pepperdine University. She is an active participant in the investor relations community and currently sits on the Board of Directors for the National Investor Relations Institute (NIRI) and has been recognized as a NIRI Fellow. She also holds the Investor Relations Charter (IRC) credential.